Key Takeaways Novo Nordisk submitted an NDA for CagriSema, a once-weekly injection for long-term weight control in adults.Novo Nordisk said CagriSema delivered up to 22.7% weight loss in REDEFINE 1 and 15.7% in REDEFINE 2.NVO is diversifying beyond semaglutide as GLP-1 competition and pricing pressure weigh on recent growth.Novo Nordisk (NVO) announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body w ...